Fosnetupitant Chloride Hydrochloride

CHEMBL3989919 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
761.5 g/mol
LogP
Phase
4

A specific salt form of fosnetupitant, an intravenous prodrug of netupitant used in combination regimens to prevent nausea and vomiting associated with highly emetogenic chemotherapy. This formulation is converted to active netupitant in the body, which then blocks neurokinin-1 receptors involved in the vomiting reflex. The chloride hydrochloride salt improves stability and solubility for intravenous use.

Peso molecular

761,5000 g/mol

TPSA

103,00 Ų

Mecanismo de acción

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)(O)O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.[Cl-]

InChI

InChI=1S/C31H35F6N4O5P.2ClH/c1-20-8-6-7-9-24(20)25-17-27(40-10-12-41(5,13-11-40)19-46-47(43,44)45)38-18-26(25)39(4)28(42)29(2,3)21-14-22(30(32,33)34)16-23(15-21)31(35,36)37;;/h6-9,14-18H,10-13,19H2,1-5H3,(H-,43,44,45);2*1H

Molecular Formula

C31H37Cl2F6N4O5P

HBD / HBA

3 / 14

Enlaces Rotables

8

Átomos Pesados

49

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A specific salt form of fosnetupitant, an intravenous prodrug of netupitant used in combination regimens to prevent nausea and vomiting associated with highly emetogenic chemotherapy. This formulation is converted to active netupitant in the body, which then blocks neurokinin-1 receptors involved in the vomiting reflex. The chloride hydrochloride salt improves stability and solubility for intravenous use.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Fosnetupitant Chloride Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989919. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 86764535. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.